Verastem, Inc. Capital Expenditures Incurred but Not yet Paid
Verastem, Inc. (VSTM) reported Capital Expenditures Incurred but Not yet Paid of $7.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2025-05-13.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2026-03-04
- Verastem, Inc. capital expenditures incurred but not yet paid for the quarter ending 2024-03-31 was $7.00K.
- Verastem, Inc. capital expenditures incurred but not yet paid for the quarter ending 2020-12-31 was $0.00.
- Verastem, Inc. capital expenditures incurred but not yet paid for the quarter ending 2020-09-30 was $211.00K.
- Verastem, Inc. capital expenditures incurred but not yet paid for the quarter ending 2020-06-30 was -$7.00K.
- Verastem, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $7.00K.
- Verastem, Inc. capital expenditures incurred but not yet paid for fiscal 2020 was $217.00K.
- Verastem, Inc. capital expenditures incurred but not yet paid for fiscal 2014 was $196.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|
| 2024-03-31 | $7.00K 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | $7.00K 10-K · filed 2026-03-04 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $211.00K derived: sum of 2 quarters · filed 2023-03-14 | $204.00K derived: sum of 3 quarters · filed 2023-03-14 | $217.00K 10-K · filed 2023-03-14 |
| 2020-09-30 | $211.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $204.00K derived: sum of 2 quarters · filed 2021-11-04 | $217.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | -$7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02 | $6.00K 10-Q · filed 2021-08-02 | ||
| 2020-03-31 | $13.00K 10-Q · filed 2021-05-11 | |||
| 2019-06-30 | $7.00K 10-Q · filed 2020-08-10 | |||
| 2018-06-30 | $358.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $527.00K 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | $169.00K 10-Q · filed 2019-05-09 | |||
| 2016-06-30 | $39.00K 10-Q · filed 2017-08-08 | |||
| 2015-03-31 | $8.00K 10-Q · filed 2016-05-09 | |||
| 2014-12-31 | $196.00K 10-K · filed 2017-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |